CYSLTR1 and pancreatic ductal adenocarcinoma: The chemo-preventive effect and therapeutic potential of montelukast on pancreatic cancer was studied with a Syrian golden hamster model, using N-nitrosobis (2-oxopropyl) amine (BOP) to induce pancreatic ductal carcinomas, which were shown to be similar to those in humans morphologically and molecularly; montelukast suppressed pancreatic carcinogenesis by suppressing cell proliferation via the LTD4-CysLT1R axis [62].